Cynthia Sirard

8PUBLICATIONS
41CO-AUTHORS
ChemotherapyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 23, 2026
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.

|Jul 10, 2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim

|Oct 21, 2024
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.

Samuel J Klempner, Mohamad Bassam Sonbol, Zev A Wainberg

|Feb 10, 2024
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

David R Wise, Russell K Pachynski, Samuel R Denmeade

|May 02, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.

Diwakar Davar, Roberta Zappasodi, Hong Wang

|Sep 05, 2021
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.

Samuel J Klempner, Johanna C Bendell, Victoria Meucci Villaflor

Pageof 2

Frequent Collaborators

5 joint publications

Samuel J Klempner

3 joint publications

Jaffer A Ajani

3 joint publications

Calvin Jia

2 joint publications

Devalingam Mahalingam